Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels

References

• Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomesThe Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–983.
   PubMedGoogle Scholar
• Hedreen JC, Peyser CE, Folstein SE, et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett. 1991;133(2):257–261.
   PubMed Web of Science ®Google Scholar
• Kiyama H, Seto-Ohshima A, Emson PC. Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington’s disease. Brain Res. 1990;525(2):209–214.
   PubMed Web of Science ®Google Scholar
• Cardoso F. Differential diagnosis of Huntington’s disease: what the clinician should know. Neurodegener Dis Manag. 2014;4(1):67–72.
   PubMedGoogle Scholar
• Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci. 2020;21(6):21.
   Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with huntington’s disease. N Engl J Med. 2019;380(24):2307–2316.
   PubMed Web of Science ®Google Scholar
• Siekierka JJ, Hung SH, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341(6244):755–757.
   PubMed Web of Science ®Google Scholar
• Cioffi DL, Hubler TR, Scammell JG. Organization and function of the FKBP52 and FKBP51 genes. Curr Opin Pharmacol. 2011;11(4):308–313.
   PubMed Web of Science ®Google Scholar
• Van Duyne GD, Standaert RF, Karplus PA, et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science. 1991;252:839–842.
   PubMed Web of Science ®Google Scholar
• Van Duyne GD, Standaert RF, Karplus PA, et al. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol. 1993;229(1):105–124.
   PubMed Web of Science ®Google Scholar
• Hartmann J, Wagner KV, Liebl C, et al. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology. 2012;62(1):332–339.
   PubMed Web of Science ®Google Scholar
• Schreiber KH, Ortiz D, Academia EC, et al. Rapamycin-mediatedmTORC2 mTORC2 inhibition is determined by the relative expression of FK506-binding FK506-binding proteins. Aging Cell. 2015;14(2):265–273.
   PubMed Web of Science ®Google Scholar
• Hausch F, Kozany C, Theodoropoulou M, et al. FKBPs and the Akt/mTOR pathway. Cell Cycle. 2013;12(15):2366–2370.
   PubMed Web of Science ®Google Scholar
• Huang S, Pj H. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371–377.
   PubMed Web of Science ®Google Scholar
• Yao YL, Liang YC, Huang HH, et al. FKBPs in chromatin modification and cancer. Curr Opin Pharmacol. 2011;11(4):301–307.
   PubMed Web of Science ®Google Scholar
• Gaali S, Kirschner A, Cuboni S, et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol. 2015;11(1):33–37.
   PubMed Web of Science ®Google Scholar
• Harrar Y, Bellini C, Jd F. FKBPs: at the crossroads of folding and transduction. Trends Plant Sci. 2001;6(9):426–431.
   PubMed Web of Science ®Google Scholar
• Riggs DL, Cox MB, Tardif HL, et al. Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Mol Cell Biol. 2007;27(24):8658–8669.
   PubMed Web of Science ®Google Scholar
• Wochnik GM, Ruegg J, Abel GA, et al. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 2005;280(6):4609–4616.
   PubMed Web of Science ®Google Scholar
• Wu B, Li P, Liu Y, et al. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci U S A. 2004;101(22):8348–8353.
   PubMed Web of Science ®Google Scholar
• Blair LJ, Criado-Marrero M, Zheng D, et al. The Disease-Associated Chaperone FKBP51 Impairs Cognitive Function by Accelerating AMPA Receptor Recycling. eNeuro. 2019;6(1). doi:https://doi.org/10.1523/ENEURO.0242-18.2019.
   Google Scholar
• Zgajnar NR, De Leo SA, Lotufo CM, et al. Biological Actions of the Hsp90-binding Immunophilins FKBP51 and FKBP52. Biomolecules. 2019;9(2):52. doi:https://doi.org/10.3390/biom9020052.
   Google Scholar
• O’Leary JC 3rd, Dharia S, Blair LJ, et al. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS One. 2011;6(9):e24840.
   PubMed Web of Science ®Google Scholar
• Touma C, Gassen NC, Herrmann L, et al. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry. 2011;70(10):928–936.
   PubMed Web of Science ®Google Scholar
• Albu S, Romanowski CP, Letizia Curzi M, et al. Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J Sleep Res. 2014;23(2):176–185.
   PubMed Web of Science ®Google Scholar
• Storer CL, Dickey CA, Galigniana MD, et al. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab. 2011;22(12):481–490.
   PubMed Web of Science ®Google Scholar
• Uk J, Koren J 3rd, Si B, et al. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci. 2010;30(2):591–599.
   PubMed Web of Science ®Google Scholar
• Criado-Marrero M, Rein T, Binder EB, et al. Hsp90 and FKBP51: complex regulators of psychiatric diseases. Philos Trans R Soc Lond B Biol Sci. 2018;373(1738):373.
   Google Scholar
• Taler-Vercic A, Hasanbasic S, Berbic S, et al. Proline residues as switches in conformational changes leading to amyloid fibril formation. Int J Mol Sci. 2017;18(3):18.
   Web of Science ®Google Scholar
• Schmidt U, Buell DR, Ionescu IA, et al. A role for synapsin in FKBP51 modulation of stress responsiveness: convergent evidence from animal and human studies. Psychoneuroendocrinology. 2015;52:43–58.
   PubMed Web of Science ®Google Scholar
• Daskalakis NP, Binder EB. Schizophrenia in the spectrum of gene-stress interactions: the FKBP5 example. Schizophr Bull. 2015;4130(2):323–9591-9.
   Google Scholar
• Blair LJ, Nordhues BA, Hill SE, et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013;123(10):4158–4169.
   PubMed Web of Science ®Google Scholar
• Boonying W, Joselin A, Huang E, et al. Pink1 regulates FKBP5 FKBP5 interaction withAKT/PHLPP AKT/PHLPP and protects neurons from neurotoxin stress induced byMPP(.)MPP+. J Neurochem. 2019;150(3):312–329.
   PubMed Web of Science ®Google Scholar
• Li H, Su P, Lai TK, et al. The glucocorticoid receptor-FKBP51 complex contributes to fear conditioning and posttraumatic stress disorder. J Clin Invest. 2020;130(2):877–889.
   PubMed Web of Science ®Google Scholar
• Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: the FKBP5 model. Biol Psychiatry. 2018;83(10):821–830.
   PubMed Web of Science ®Google Scholar
• Gerard M, Deleersnijder A, Daniels V, et al. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson’s disease-like pathology. J Neurosci. 2010;30(7):2454–2463.
   PubMed Web of Science ®Google Scholar
• Gold BG, Nutt JG. Neuroimmunophilin ligands in the treatment of Parkinson’s disease. Curr Opin Pharmacol. 2002;2(1):82–86.
   PubMed Web of Science ®Google Scholar
• Gerard M, Debyser Z, Desender L, et al. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. Faseb J. 2006;20(3):524–526.
   PubMedGoogle Scholar
• Dehay B, Bertolotti A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem. 2006;281130(47):15877–15889.
   Google Scholar
• Darnell G, Orgel JP, Pahl R, et al. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol. 2007;374(3):688–704.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Thakur AK, Chellgren VM, et al. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol. 2006;355(3):524–535.
   PubMed Web of Science ®Google Scholar
• Wetzel R. Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol. 2012;421(4–5):466–490.
   PubMed Web of Science ®Google Scholar
• Wagner AS, Politi AZ, Ast A, et al. Self-assembly of mutant huntingtin exon-1 fragments into large complex fibrillar structures involves nucleated branching. J Mol Biol. 2018;430(12):1725–1744.
   PubMed Web of Science ®Google Scholar
• Ring KL, An MC, Zhang N, O’Brien RN, Ramos EM, Gao F, et al. Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human huntington’s disease neural stem cells. Stem Cell Reports. 2015;5(6):1023–1038.
   PubMed Web of Science ®Google Scholar
• Balsevich G, Hausl AS, Meyer CW, et al. Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nat Commun. 2017;8(1):1725.
   PubMedGoogle Scholar
• Heikkinen T, Lehtimaki K, Vartiainen N, et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS One. 2012;7(12):e50717.
   PubMed Web of Science ®Google Scholar
• Menalled LB, Kudwa AE, Miller S, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One. 2012;7(12):e49838.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Cantle JP, Chatzopoulou D, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci. 2016;19(4):623–633.
   PubMed Web of Science ®Google Scholar
• Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
   PubMed Web of Science ®Google Scholar
• Cummings DM, Alaghband Y, Hickey MA, et al. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington’s disease. J Neurophysiol. 2012;107(2):677–691.
   PubMed Web of Science ®Google Scholar
• Menalled L, El-Khodor BF, Patry M, et al. Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol Dis. 2009;35107(3):319–36677-691.
   Google Scholar
• Menalled LB, Sison JD, Dragatsis I, et al. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11–26.
   PubMed Web of Science ®Google Scholar
• Neto JL, Lee JM, Afridi A, et al. Genetic contributors to intergenerational CAG repeat instability in huntington’s disease knock-in mice. Genetics. 2017;205(2):503–516.
   PubMed Web of Science ®Google Scholar
• Franich NR, Basso M, Andre EA, et al. Striatal mutant huntingtin protein levels decline with age in homozygous huntington’s disease knock-in mouse models. J Huntington’s Dis. 2018;7(2):137–150.
   PubMed Web of Science ®Google Scholar
• Reindl W, Baldo B, Schulz J, et al. Meso scale discovery-based assays for the detection of aggregated huntingtin. PLoS One. 2019;14(3):e0213521.
   PubMed Web of Science ®Google Scholar
• An MC, O’Brien RN, Zhang N, et al. Polyglutamine Disease Modeling: epitope Based Screen for Homologous Recombination using CRISPR/Cas9 System. PLoS currents. 2014;6. doi:https://doi.org/10.1371/currents.hd.0242d2e7ad72225efa72f6964589369a.
   Google Scholar
• An MC, Zhang N, Scott G, et al. Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell. 2012;11(2):253–263.
   PubMed Web of Science ®Google Scholar
• Al-Ramahi I, Lu B, Di Paola S, et al. High-throughput functional analysis distinguishes pathogenic, nonpathogenic, and compensatory transcriptional changes in neurodegeneration. Cell Syst. 2018;7(1):28–40 e4.
   PubMed Web of Science ®Google Scholar
• Blair LJ, Baker JD, Sabbagh JJ, et al. The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer’s disease. J Neurochem. 2015;133(1):1–13.
   PubMed Web of Science ®Google Scholar
• Jain A, Lamark T, Sjottem E, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem. 2010;285(29):22576–22591.
   PubMed Web of Science ®Google Scholar
• Panek J, Kolar M, Vohradsky J, et al. An evolutionary conserved pattern of 18S rRNA sequence complementarity to mRNA 5ʹ 5′ UTRs and its implications for eukaryotic gene translation regulation. Nucleic Acids Res. 2013;41(16):7625–7634.
   PubMed Web of Science ®Google Scholar
• Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131–24145.
   PubMed Web of Science ®Google Scholar
• Menzies FM, Rubinsztein DC. Broadening the therapeutic scope for rapamycin treatment. Autophagy. 2010;6(2):286–287.
   PubMed Web of Science ®Google Scholar
• Quarles E, Basisty N, Chiao YA, et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell. 2020;19(2):e13086.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Krishna G, Imarisio S, et al. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet. 2008;17(2):170–178.
   PubMed Web of Science ®Google Scholar
• Zhang N, Li B, Al-Ramahi I, et al. Inhibition of lipid signaling enzyme diacylglycerol kinase epsilon attenuates mutant huntingtin toxicity. J Biol Chem. 2012;28717(25):13170–13178.
   Google Scholar
• Giustiniani J, Sineus M, Sardin E, et al. Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer’s disease and FTDP-17. J Alzheimers Dis. 2012;29:471–483.
   PubMed Web of Science ®Google Scholar
• Avramut M, Achim CL. Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav. 2002;77(4–5):463–468.
   PubMed Web of Science ®Google Scholar
• Caraveo G, Soste M, Cappelleti V, et al. FKBP12 contributes to alpha-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome. Proc Natl Acad Sci U S A. 2017;114(52):E11313–e22.
   PubMed Web of Science ®Google Scholar
• Caron NS, Desmond CR, Xia J, et al. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc Natl Acad Sci U S A. 2013;110(36):14610–14615.
   PubMed Web of Science ®Google Scholar
• Neveklovska M, Clabough EB, Steffan JS, et al. Deletion of the huntingtin proline-rich region does not significantly affect normal huntingtin function in mice. J Huntington’s Dis. 2012;1(1):71–87.
   PubMedGoogle Scholar
• Sun CS, Lee CC, Li YN, et al. Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. Sci Rep. 2015;5(1):14992.
   PubMedGoogle Scholar
• Martin DD, Ladha S, Ehrnhoefer DE, et al. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2015;38(1):26–35.
   PubMed Web of Science ®Google Scholar
• Guo F, Liu X, Cai H, et al. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol. 2018;28(1):3–13.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282(8):5641–5652.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Ravikumar B, Floto RA, et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009;16(1):46–56.
   PubMed Web of Science ®Google Scholar
• Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-lowering therapies for huntington disease: a review of the evidence of potential benefits and risks. JAMA Neurol. 2020;77(6):764.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36(6):585–595.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019;575(7781):203–209.
   PubMed Web of Science ®Google Scholar
• Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s Huntington’s disease. Nat Neurosci. 2010;13(5):567–576.
   PubMed Web of Science ®Google Scholar
• Steffan JS. Does Huntingtin play a role in selective macroautophagy? Cell Cycle. 2010;9(17):3401–3413.
   PubMed Web of Science ®Google Scholar
• Gassen NC, Hartmann J, Zschocke J, et al. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. PLoS Med. 2014;11(11):e1001755.
   PubMed Web of Science ®Google Scholar
• Cheung-Flynn J, Prapapanich V, Cox MB, et al. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol. 2005;1936(6):1654–66585-595.
   Google Scholar
• Kl R, An MC, Zhang N, et al. Genomic Analysis Reveals Disruption of Striatal Neuronal Development and Therapeutic Targets in Human Huntington’s Disease Neural Stem Cells. Stem Cell Reports. 2015;5(6):1023–1038.
   PubMed Web of Science ®Google Scholar
• Kemp PJ, Rushton DJ, Yarova PL, et al. Improving and accelerating the differentiation and functional maturation of human stem cell-derived neurons: role of extracellular calcium and GABA. J Physiol. 2016;594(22):6583–6594.
   PubMed Web of Science ®Google Scholar